Group 1 - The trade negotiations between India and the United States are stalled due to disagreements over tariffs on auto parts, steel, and agricultural products, making it difficult to reach an agreement before the July 9 deadline set by Trump [1][2] - India has proposed a "zero-for-zero" tariff arrangement for specific goods, including steel, auto parts, and pharmaceuticals, based on reciprocity and limited to a certain quantity of imports [1][2] - The Indian delegation is expected to travel to Washington for negotiations, but the focus may shift towards a broader agreement rather than a rushed temporary deal [1][3] Group 2 - India is pushing for the removal of a 26% reciprocal tariff set to take effect on July 9 and is seeking concessions from the U.S. on existing tariffs for steel and auto parts [1][3] - Despite the stalled negotiations, India emphasizes its commitment to establishing a long-term economic partnership with the U.S. while maintaining policy independence [3][4] - India has proposed to reduce tariffs on almonds, pistachios, and walnuts, and is willing to offer preferential treatment for U.S. imports in sectors like energy, automotive, and defense [2][3] Group 3 - The bilateral trade agreement aims to increase trade from approximately $191 billion in 2024 to $500 billion by 2030, as agreed by Modi and Trump [3] - India is also pursuing free trade agreements with the European Union and has recently completed negotiations with the United Kingdom to hedge against potential changes in U.S. policy [3][4] - Data shows that India's exports to the U.S. increased to $17.25 billion from April to May, up from $14.17 billion in the same period last year, indicating limited impact from the average 10% tariff increase in early April [4]

Group 1 - India has proposed a "zero-for-zero" tariff arrangement for specific goods, including steel, auto parts, and pharmaceuticals, during trade negotiations with the US, based on reciprocity and limited to a certain quantity of imports [1][2] - The US has expressed concerns regarding India's quality control regulations, viewing them as non-tariff trade barriers that restrict market access for American companies [1][2] - India's exports of pharmaceuticals to the US are valued at $10.5 billion, while engineering products exports amount to $19.1 billion in the new fiscal year [1] Group 2 - The proposal for "zero-for-zero" tariffs has garnered attention, but it is unlikely to be adopted due to differing economic development levels between the US and India [2] - The number of quality control orders in India has increased significantly from 14 before 2014 to over 140 since 2017, raising transparency and fairness concerns [2] - President Trump claimed that India agreed to reduce tariffs on US imports to "zero," although India has not officially confirmed this statement as negotiations are ongoing [3]